The Latest Breaking News from AbCellera

An Antibody Injection Cut Hot Flashes by 83 Percent in a Mid-Stage Trial of 92 Women

AbCellera reports that a single injection reduced moderate-to-severe hot flashes by 83% at 4 weeks in a Phase 2 trial of 92 postmenopausal women.

Medical Daily · Aug 13

AbCellera Biologics Bets on Hot Flash Antibody as Pipeline Pivot Gains Steam

AbCellera Biologics (NASDAQ:ABCL) is emphasizing its transition from a partner-based antibody discovery business to a proprietary drug development company, Chief Financial Officer Andrew Booth said during a company presentation focused on the biotech’s pipeline and lead clinical program. Booth said

MarketBeat · Jun 4

AbCellera Biologics Q1 Earnings Call Highlights

AbCellera Biologics (NASDAQ:ABCL) said its first quarter of 2026 was marked by progress in its internal drug pipeline, including interim Phase 1 data for its lead program, ABCL635, and continued preparation for multiple clinical catalysts expected over the next two years. President and CEO Dr. Carl

MarketBeat · May 11

Canada needs to invest more money into science innovation to help prevent the next global crisis

Canada has lagged behind its peer nations in innovation for decades. Currently, Canada is ranked 11th out of the 16 similarly developed countries assessed. While our “C” grade is a moderate improvement over our previous “D” grade, innovation still remains a barrier to high-quality job creation and economic prosperity in…

The Conversation · Jun 28, 2022

Will AI turbocharge the hunt for new drugs?

Advocates point to the pandemic as proof of its value in healthcare even as critics dismiss its use in drug discovery as ‘hype’

Financial Times · Mar 20, 2022